Jobs for Engineers, IT, Physicians & Scientists

CatalYm GmbH

CatalYm GmbH

Your career at CatalYm

CatalYm has identified GDF-15 as a key cancer therapy resistance mechanism and is developing a safe and efficacious immune therapy for solid tumors. GDF-15, an immunosuppressant important for feto-maternal tolerance, is hijacked by cancer cells to evade immune system attacks. Visugromab, CatalYm’s lead antibody, has demonstrated durable anti-tumor efficacy with long-lasting objective responses in relapsed and refractory metastatic solid tumor patients in combination with anti-PD-1. CatalYm is now advancing into Phase 2b studies to confirm visugromab as a new class of cancer immunotherapy in a broad range of anti-cancer regimens.

Application & Start your career at CatalYm

How to apply

  • Online application

Company Details for CatalYm


CatalYm GmbH
Am Klopferspitz 19
82152 Planegg
Show Map